Acknowledgement
This work was supported by grant from Inje University, 2023 (No. 20230017).
References
- Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet. 2012;379:1234-1244. https://doi.org/10.1016/s0140-6736(11)61177-x
- Lopez C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022;8:78. https://doi.org/10.1038/s41572-022-00404-3
- Salles G, Barrett M, Foa R, Maurer J, O'Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232-2273. https://doi.org/10.1007/s12325-017-0612-x
- Xue C, Wang X, Zhang L, Qu Q, Zhang Q, Jiang Y. Ibrutinib in B-cell lymphoma: single fighter might be enough? Cancer Cell Int. 2020;20:467. https://doi.org/10.1186/s12935-020-01518-y
- Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, et al. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017; 129:1155-1165. https://doi.org/10.1182/blood-2016-06-722900
- Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006;42:441-453. https://doi.org/10.1358/dot.2006.42.7.985637
- Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist. 2012;17:536-542. https://doi.org/10.1634/theoncologist.2011-0461
- Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010-1014. https://doi.org/10.1126/science.1092734
- Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998;4:1099-1109. https://doi.org/10.1093/molehr/4.12.1099
- Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286-3295. https://doi.org/10.1182/blood-2014-02-548610
- Jeong Y, Kim SB, Yang CE, Yu MS, Choi WS, Jeon Y, et al. Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt's lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib. Front Oncol. 2023;13:1252658. https://doi.org/10.3389/fonc.2023.1252658
- Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol. 2007;18 Suppl 6:vi26-30. https://doi.org/10.1093/annonc/mdm220
- Kim SB, Yang CE, Jeong Y, Yu M, Choi WS, Lim JY, et al. Dual targeting of EZH2 degradation and EGFR/HER2 inhibition for enhanced efficacy against Burkitt's lymphoma. Cancers (Basel). 2023;15:4472. https://doi.org/10.3390/cancers15184472
- Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 2002;13:978-988. https://doi. org/10.1091/mbc.01-05-0272
- Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815. https://doi.org/10.1038/sj.onc.1204252
- Srivastava N, Saxena AK. Caspase-3 activators as anticancer agents. Curr Protein Pept Sci. 2023;24:783-804. https://doi.org/10.2174/1389203724666230227115305
- Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, et al. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin. 2007;28:1057-1066. https://doi.org/10.1111/j.1745-7254.2007.00588.x
- Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 2014;33:3992-4002. https://doi.org/10.1038/onc.2013.368
- Park C, Cha HJ, Lee H, Hwang-Bo H, Ji SY, Kim MY, et al. Induction of G2/M cell cycle arrest and apoptosis by Genistein in human bladder cancer T24 cells through inhibition of the ROS-dependent PI3k/Akt signal transduction pathway. Antioxidants (Basel). 2019;8:327. https://doi.org/10.3390/antiox8090327
- Xia W, Spector S, Hardy L, Zhao S, Saluk A, Alemane L, et al. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. Proc Natl Acad Sci U S A. 2000;97:7494-7499. https://doi.org/10.1073/pnas.97.13.7494